Keywords:
felzartamab, felzartamab’s R&D Progress, Mechanism of Action for felzartamab, drug target for felzartamab.
Description:
This article summarized the latest R&D progress of felzartamab, the Mechanism of Action for felzartamab, and the drug target R&D trends for felzartamab.
Text:
felzartamab‘s R&D Progress
Felzartamab is a monoclonal antibody drug that targets CD38, a protein found on the surface of certain cells. It is being developed by MorphoSys AG, a pharmaceutical company specializing in biomedicine. The drug is currently in the highest phase of development, known as NDA/BLA globally.
Felzartamab has shown potential in treating a range of diseases across various therapeutic areas. These include neoplasms (abnormal growth of cells), immune system diseases, skin and musculoskeletal diseases, urogenital diseases, cardiovascular diseases, and hemic and lymphatic diseases. The drug has demonstrated efficacy in multiple indications, including multiple myeloma, glomerulonephritis (specifically IgA and membranous types), systemic lupus erythematosus, and leukemia.
Felzartamab has a notable feature of being classified as an orphan drug. Such drugs are specifically created to cure rare diseases or conditions that affect only a small number of patients. This classification offers several advantages and benefits to the drug manufacturer, including market exclusivity and financial assistance.
As a monoclonal antibody, Felzartamab is designed to specifically target CD38, a protein involved in various cellular processes. By binding to CD38, the drug aims to modulate the activity of cells and potentially inhibit the progression of diseases associated with CD38 overexpression or dysregulation.
The creation of Felzartamab is a major breakthrough in biomedicine, specifically in treating multiple myeloma, glomerulonephritis, systemic lupus erythematosus, and leukemia. Its orphan drug status underscores its ability to meet the medical needs of those suffering from these uncommon diseases.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for felzartamab: CD38 inhibitors
CD38 inhibitors are a type of medication that specifically target the CD38 protein. CD38 is an enzyme found on the surface of certain cells, including immune cells and plasma cells. By inhibiting CD38, these inhibitors can interfere with the function of CD38, which plays a role in various cellular processes.
ADCC stands for Antibody-dependent cellular phagocytosis. It is a mechanism of the immune system where immune cells, such as natural killer cells, recognize and destroy target cells that are coated with antibodies. In this process, the antibodies bind to the target cells, marking them for destruction, and the immune cells then engulf and eliminate the marked cells.
Antibody-dependent cellular phagocytosis (ADCP) effects refer to the effects of antibodies in promoting the phagocytosis (engulfment and destruction) of target cells by immune cells, such as macrophages. Similar to ADCC, ADCP involves the binding of antibodies to target cells, which triggers the immune cells to recognize and eliminate the marked cells through phagocytosis.
In summary, CD38 inhibitors are medications that target the CD38 protein, while ADCC and ADCP are immune mechanisms involving the recognition and destruction of target cells by immune cells through the action of antibodies.
Drug Target R&D Trends for felzartamab
CD38 is a multifunctional enzyme found on the surface of various cells in the human body. It plays a crucial role in regulating calcium signaling and cell adhesion processes. CD38 is primarily known for its involvement in the immune system, where it acts as a marker for immune cell activation and differentiation. Additionally, CD38 is also involved in the metabolism of NAD+ and cADPR, which are important molecules for cellular energy production and signaling. Dysregulation of CD38 has been implicated in various diseases, including autoimmune disorders, cancer, and neurodegenerative conditions. Understanding the role of CD38 is essential for developing targeted therapies and diagnostic tools in the pharmaceutical industry.
According to Patsnap Synapse, as of 7 Sep 2023, there are a total of 86 CD38 drugs worldwide, from 101 organizations, covering 55 indications, and conducting 555 clinical trials.
The current competitive landscape of target CD38 is characterized by the presence of multiple companies with drugs in different phases of development. Johnson & Johnson, Sanofi, Halozyme Therapeutics, Inc., I-MAB Biopharma Co., Ltd., and Takeda Pharmaceutical Co., Ltd. are the leading companies in terms of R&D progress and drug development.
The approved indications for drugs targeting CD38 include Multiple Myeloma, Light chain (AL) amyloidosis, and other hematologic neoplasms. Multiple Myeloma is the most common approved indication.
Monoclonal antibody, CAR-T, and Bispecific antibody are the most rapidly progressing drug types under the current target CD38. These drug types indicate intense competition and innovation in the field.
The countries with the highest development progress under the current target are the United States, Japan, and China. China has made significant progress with 2 approved drugs and several drugs in Preclinical phases.
Overall, the target CD38 presents a competitive landscape with multiple companies and drug types vying for development and approval. The future development of this target is promising, especially in the areas of Multiple Myeloma and innovative drug types such as CAR-T and Bispecific antibody.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
Overall, Felzartamab holds promise as a targeted therapy for various diseases, leveraging the specificity and potential therapeutic benefits of monoclonal antibodies. Further clinical trials and regulatory approvals will be necessary to determine its safety and efficacy, but the drug’s progress to the highest phase of development suggests it may have a positive impact on patients in the future.